Free Trial
Ends Tomorrow! Last Chance to Save $100 on MarketBeat All Access
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Claim $100 Off
Claim MarketBeat All Access Sale Promotion
NASDAQ:IMNM

Immunome Q1 2025 Earnings Report

Immunome logo
$21.66 -1.30 (-5.66%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$21.80 +0.14 (+0.63%)
As of 05/22/2026 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immunome EPS Results

Actual EPS
-$0.52
Consensus EPS
-$0.66
Beat/Miss
Beat by +$0.14
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
$2.93 million
Expected Revenue
$0.46 million
Beat/Miss
Beat by +$2.47 million
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q1 2025
Date
5/12/2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
12:00AM ET

Upcoming Earnings

Immunome's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 7, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Immunome's Q1 2025 Press ReleasePress Release
(8-K)
Immunome's Q1 2025 Quarterly reportQuarterly report
(10-Q)

Immunome Earnings Headlines

Immunome Expands Oncology Pipeline With New Phase 1 IM-1617 Trial
May 22 at 12:50 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/immunome-expands-oncology-pipeline-with-new-phase-1-im-1617-trial?utm_source=marketbeat.com&utm_medium=referral
What Offers Immunome (IMNM) a Compelling Investment Opportunity?
May 18, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/what-offers-immunome-imnm-a-compelling-investment-opportunity-1764027/
One page of the SpaceX S-1 will move this stock overnight
When SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown.tc pixel
May 24 at 1:00 AM  |  Behind the Markets (Ad)
Analysts Are Bullish on These Healthcare Stocks: Immunome (IMNM), Coherus Biosciences (CHRS)
May 15, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1935527/analysts-are-bullish-on-these-healthcare-stocks-immunome-imnm-coherus-biosciences-chrs/
Analysts Are Bullish on Top Healthcare Stocks: Immunome (IMNM), Kalaris Therapeutics (KLRS)
May 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/KLRS/pressreleases/1916606/analysts-are-bullish-on-top-healthcare-stocks-immunome-imnm-kalaris-therapeutics-klrs/
Immunome (NASDAQ:IMNM) Given "Buy" Rating at HC Wainwright
May 14, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30777525
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM) is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens. In parallel, Immunome is advancing additional candidates in solid tumors, including antibody–drug conjugates and immunomodulatory antibodies that aim to stimulate anti-tumor immune responses. Beyond oncology, the platform has been applied to infectious disease programs, where candidate antibodies against emerging viral threats have been identified and optimized for potential therapeutic or prophylactic use.

Founded in the early 2000s and headquartered in Ann Arbor, Michigan, Immunome has grown from a privately held research operation into a publicly traded company listed on the Nasdaq exchange under the ticker “IMNM.” In 2021, the company completed its initial public offering, providing capital to support ongoing clinical development and platform expansion. Led by President and Chief Executive Officer Greg Bailey, Immunome maintains collaborations with academic institutions and industry partners to advance its pipeline and explore new therapeutic applications of its discovery platform.

View Immunome Profile
Earnings Tools